muscular dystrophy-dystroglycanopathy type B5
diseaseOn this page
Also known as congenital muscular dystrophy-FKRP relatedMDC1CMDDGB5muscular dystrophy-dystroglycanopathy (congenital with or without intellectual disability), type B, 5muscular dystrophy-dystroglycanopathy (congenital with or without mental retardation), type B, 5
Summary
muscular dystrophy-dystroglycanopathy type B5 (MONDO:0011688) is a disease caused by FKRP (GenCC Definitive), with 1 cohort gene.
At a glance
- Causal gene: FKRP (GenCC Definitive)
- Cohort genes: 1
- ClinVar variants: 119
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | muscular dystrophy-dystroglycanopathy type B5 |
| Mondo ID | MONDO:0011688 |
| MeSH | C564691 |
| OMIM | 606612 |
| Orphanet | 52428 |
| DOID | DOID:0110635 |
| UMLS | C1847759 |
| MedGen | 335764 |
| GARD | 0024818 |
| Is cancer (heuristic) | no |
Also known as: congenital muscular dystrophy-FKRP related · MDC1C · MDDGB5 · muscular dystrophy-dystroglycanopathy (congenital with or without intellectual disability), type B, 5 · muscular dystrophy-dystroglycanopathy (congenital with or without mental retardation), type B, 5
Data availability: 119 ClinVar variants · 2 GenCC gene-disease records.
Disease family
Classification path: disease › human disease › disease by body system or component › nervous system disorder › congenital nervous system disorder › congenital muscular dystrophy › muscular dystrophy-dystroglycanopathy › muscular dystrophy-dystroglycanopathy, type B › muscular dystrophy-dystroglycanopathy type B5
Related subtypes (7): muscular dystrophy-dystroglycanopathy type B6, muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3, muscular dystrophy-dystroglycanopathy (congenital without intellectual disability), type B4, muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B1, muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B2, muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B14, muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type B, 15
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
119 retrieved; paginated sample, class counts are floors:
48 uncertain significance, 23 conflicting classifications of pathogenicity, 19 pathogenic/likely pathogenic, 13 likely pathogenic, 5 benign/likely benign, 5 pathogenic, 4 likely benign, 2 benign
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 1071118 | NM_024301.5(FKRP):c.540_570dup (p.Cys191fs) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1920325 | NM_024301.5(FKRP):c.949del (p.Cys317fs) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1929555 | NM_024301.5(FKRP):c.692G>A (p.Trp231Ter) | FKRP | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 197347 | NM_024301.5(FKRP):c.947C>G (p.Pro316Arg) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 282247 | NM_024301.5(FKRP):c.545A>G (p.Tyr182Cys) | FKRP | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 282866 | NM_024301.5(FKRP):c.162_165dup (p.Phe56fs) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 289473 | NM_024301.5(FKRP):c.970G>T (p.Glu324Ter) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 2913953 | NM_024301.5(FKRP):c.1208dup (p.Arg404fs) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4219 | NM_024301.5(FKRP):c.1154C>A (p.Ser385Ter) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4220 | NM_024301.5(FKRP):c.1343C>T (p.Pro448Leu) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4221 | NM_024301.5(FKRP):c.826C>A (p.Leu276Ile) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4224 | NM_024301.5(FKRP):c.946C>A (p.Pro316Thr) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4226 | NM_024301.5(FKRP):c.1364C>A (p.Ala455Asp) | FKRP | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 4232 | NM_024301.5(FKRP):c.899T>C (p.Val300Ala) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4235 | NM_024301.5(FKRP):c.1387A>G (p.Asn463Asp) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 550361 | NM_024301.5(FKRP):c.928G>T (p.Glu310Ter) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 551007 | NM_024301.5(FKRP):c.266C>T (p.Pro89Leu) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 553930 | NM_024301.5(FKRP):c.1012G>T (p.Val338Leu) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 554104 | NM_024301.5(FKRP):c.778G>T (p.Glu260Ter) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 654883 | NM_024301.5(FKRP):c.1296G>A (p.Trp432Ter) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 664273 | NM_024301.5(FKRP):c.948del (p.Cys317fs) | FKRP | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 930906 | NM_024301.5(FKRP):c.962C>A (p.Ala321Glu) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 939991 | NM_024301.5(FKRP):c.206_208del (p.Ser69del) | FKRP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 96115 | NM_024301.5(FKRP):c.941C>T (p.Thr314Met) | FKRP | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 1334893 | NM_024301.5(FKRP):c.503G>A (p.Cys168Tyr) | FKRP | Likely pathogenic | criteria provided, single submitter |
| 3584041 | NM_024301.5(FKRP):c.2T>C (p.Met1Thr) | FKRP | Likely pathogenic | criteria provided, single submitter |
| 3584042 | NM_024301.5(FKRP):c.265C>T (p.Pro89Ser) | FKRP | Likely pathogenic | criteria provided, single submitter |
| 3584043 | NM_024301.5(FKRP):c.884_885del (p.Arg295fs) | FKRP | Likely pathogenic | criteria provided, single submitter |
| 3584044 | NM_024301.5(FKRP):c.899T>A (p.Val300Glu) | FKRP | Likely pathogenic | criteria provided, single submitter |
| 3584045 | NM_024301.5(FKRP):c.927C>A (p.Tyr309Ter) | FKRP | Likely pathogenic | criteria provided, single submitter |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 15 · Orphanet: 6 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| FKRP | Definitive | Autosomal recessive | autosomal recessive limb-girdle muscular dystrophy type 2I | 15 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| FKRP | Orphanet:34515 | FKRP-related limb-girdle muscular dystrophy R9 |
| FKRP | Orphanet:370959 | Congenital muscular dystrophy with cerebellar involvement |
| FKRP | Orphanet:370968 | Congenital muscular dystrophy with intellectual disability |
| FKRP | Orphanet:370980 | Congenital muscular dystrophy without intellectual disability |
| FKRP | Orphanet:588 | Muscle-eye-brain disease |
| FKRP | Orphanet:899 | Walker-Warburg syndrome |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| FKRP | HGNC:17997 | ENSG00000181027 | Q9H9S5 | Ribitol 5-phosphate transferase FKRP | gencc,clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| FKRP | Ribitol 5-phosphate transferase FKRP | Catalyzes the transfer of a ribitol 5-phosphate from CDP-L-ribitol to the ribitol 5-phosphate previously attached by FKTN/fukutin to the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phos… |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 1 | 1.8× | 0.558 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| FKRP | Other/Unknown | no | LicD/FKTN/FKRP_NTP_transf, LicD_transferase, FKRP_N |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| cardiac muscle of right atrium | 1 |
| hindlimb stylopod muscle | 1 |
| left ventricle myocardium | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| FKRP | 230 | ubiquitous | marker | left ventricle myocardium, cardiac muscle of right atrium, hindlimb stylopod muscle |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| FKRP | 1,436 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| FKRP | Q9H9S5 | 8 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 1. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Matriglycan biosynthesis on DAG1 | 1 | 815.7× | 0.001 | FKRP |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| pentitol metabolic process | 1 | 16852.0× | 0.001 | FKRP |
| filtration diaphragm assembly | 1 | 16852.0× | 0.001 | FKRP |
| pentose metabolic process | 1 | 8426.0× | 0.001 | FKRP |
| creatine metabolic process | 1 | 4213.0× | 0.001 | FKRP |
| connective tissue development | 1 | 4213.0× | 0.001 | FKRP |
| oxygen metabolic process | 1 | 4213.0× | 0.001 | FKRP |
| maintenance of protein localization in endoplasmic reticulum | 1 | 3370.4× | 0.002 | FKRP |
| localization of cell | 1 | 2808.7× | 0.002 | FKRP |
| connective tissue replacement | 1 | 2407.4× | 0.002 | FKRP |
| diaphragm development | 1 | 1872.4× | 0.002 | FKRP |
| protein import | 1 | 1685.2× | 0.002 | FKRP |
| skeletal muscle fiber differentiation | 1 | 1685.2× | 0.002 | FKRP |
| response to alcohol | 1 | 1532.0× | 0.002 | FKRP |
| reelin-mediated signaling pathway | 1 | 1203.7× | 0.002 | FKRP |
| respiratory system process | 1 | 936.2× | 0.002 | FKRP |
| protein O-linked glycosylation via mannose | 1 | 936.2× | 0.002 | FKRP |
| glial cell differentiation | 1 | 887.0× | 0.002 | FKRP |
| skeletal muscle tissue regeneration | 1 | 887.0× | 0.002 | FKRP |
| protein tetramerization | 1 | 624.1× | 0.003 | FKRP |
| neuromuscular process | 1 | 526.6× | 0.003 | FKRP |
| basement membrane organization | 1 | 510.7× | 0.003 | FKRP |
| adult walking behavior | 1 | 495.6× | 0.003 | FKRP |
| glycolytic process | 1 | 383.0× | 0.004 | FKRP |
| heart morphogenesis | 1 | 374.5× | 0.004 | FKRP |
| camera-type eye development | 1 | 358.6× | 0.004 | FKRP |
| response to activity | 1 | 324.1× | 0.004 | FKRP |
| response to glucocorticoid | 1 | 324.1× | 0.004 | FKRP |
| bone mineralization | 1 | 271.8× | 0.005 | FKRP |
| phosphatidylinositol 3-kinase/protein kinase B signal transduction | 1 | 210.7× | 0.006 | FKRP |
| muscle contraction | 1 | 208.1× | 0.006 | FKRP |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| FKRP | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 1 | FKRP |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| FKRP | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: FKRP